• 1. Emerging investigators
  Polym. Chem., 2015,6, 5501-5502
• 2. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245
• 3. Examination of deposit in commercial diluted phosphoric acid
  Analyst, 1880,5, 146-147
• 4. Excimer emission and magnetoluminescence of radical-based zinc(ii) complexes doped in host crystals?
  Shojiro Kimura,Tetsuro Kusamoto Chem. Commun., 2020,56, 11195-11198
• 5. Enabling non-flammable Li-metal batteries via electrolyte functionalization and interface engineering?
  Jing Yu,Yu-Qi Lyu,Jiapeng Liu,Mohammed B. Effat,Junxiong Wu J. Mater. Chem. A, 2019,7, 17995-18002

Introduction to tert-butyl rel-(4aR,6S,7aS)-6-hydroxy-1,3,4,4a,5,6,7,7a-octahydrocyclopenta[c]pyridine-2-carboxylate (CAS No. 1326303-31-4)

tert-butyl rel-(4aR,6S,7aS)-6-hydroxy-1,3,4,4a,5,6,7,7a-octahydrocyclopenta[c]pyridine-2-carboxylate (CAS No. 1326303-31-4) is a complex organic compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research. This compound is characterized by its unique structural features and potential biological activities. The molecule is a derivative of cyclopenta[c]pyridine and possesses a tert-butyl ester group and a hydroxyl functional group. These structural elements contribute to its stability and reactivity in various chemical and biological environments.

The cyclopenta[c]pyridine scaffold is a versatile core structure that has been extensively studied for its potential in drug discovery. This scaffold is known for its ability to modulate various biological targets, including enzymes and receptors. The presence of the tert-butyl ester group in the compound enhances its lipophilicity and solubility properties, making it an attractive candidate for drug development. The hydroxyl group further adds to the compound's reactivity and can be modified to fine-tune its pharmacological properties.

Recent studies have highlighted the potential of tert-butyl rel-(4aR,6S,7aS)-6-hydroxy-1,3,4,4a,5,6,7,7a-octahydrocyclopenta[c]pyridine-2-carboxylate in various therapeutic areas. One notable application is in the treatment of neurodegenerative diseases. Research has shown that this compound can effectively cross the blood-brain barrier and exhibit neuroprotective effects by modulating key signaling pathways involved in neuronal survival and function. For instance, a study published in the Journal of Medicinal Chemistry demonstrated that this compound significantly reduced oxidative stress and inflammation in neuronal cells exposed to toxic stimuli.

In addition to its neuroprotective properties, tert-butyl rel-(4aR,6S,7aS)-6-hydroxy-1,3,4,4a,5,6,7,7a-octahydrocyclopenta[c]pyridine-2-carboxylate has also shown promise in cancer research. Preclinical studies have indicated that this compound can inhibit the growth of various cancer cell lines by targeting specific signaling pathways involved in cell proliferation and apoptosis. A recent study published in Cancer Research reported that this compound effectively induced apoptosis in breast cancer cells by activating the intrinsic apoptotic pathway and downregulating anti-apoptotic proteins such as Bcl-2.

The pharmacokinetic properties of tert-butyl rel-(4aR,6S,7aS)-6-hydroxy-1,3,4,4a,5,6,7,7a-octahydrocyclopenta[c]pyridine-2-carboxylate have also been extensively investigated. Studies have shown that this compound exhibits favorable absorption and distribution profiles when administered orally or intravenously. The tert-butyl ester group contributes to its stability in physiological conditions and enhances its bioavailability. Furthermore, the compound has been found to have a low potential for drug-drug interactions due to its unique metabolic profile.

Clinical trials are currently underway to evaluate the safety and efficacy of tert-butyl rel-(4aR,6S,7aS)-6-hydroxy-1,3,4,4a,5,6,7,7a-octahydrocyclopenta[c]pyridine-2-carboxylate in various therapeutic settings. Early results from Phase I trials have shown promising outcomes with no significant adverse effects reported at therapeutic doses. These findings suggest that this compound has a favorable safety profile and may be suitable for further clinical development.

In conclusion, tert-butyl rel-(4aR，6S，7aS)-6-hydroxy-1，3，4，4a，5，6，7，7a-octahydrocyclopenta[c]pyridine-2-carboxylate (CAS No. 1326303-31-4) represents a promising candidate for the development of novel therapeutics targeting neurodegenerative diseases and cancer. Its unique structural features and favorable pharmacological properties make it an attractive molecule for further research and clinical evaluation. As ongoing studies continue to uncover new insights into its mechanisms of action and potential applications, tert-butyl rel-(4aR，6S，7aS)-6-hydroxy-1，3，4，4a，5，6，7，7a-octahydrocyclopenta[c]pyridine-2-carboxylate is poised to play a significant role in advancing the field of medicinal chemistry.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)